Abstract
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle pain and myoglobinuria may be present. The severity of illness ranges from asymptomatic elevations in serum muscle enzymes to life-threatening disease associated with extreme enzyme elevations, electrolyte imbalances, acute kidney injury and disseminated intravascular coagulation. We present a case of an African American male with severe hemophilia A and history of factor VIII inhibitor, maintained on emicizumab prophylaxis, who developed rhabdomyolysis with a symptomatic hyperCKemia. To date, there is no known link between rhabdomyolysis to emicizumab. This report brings to light the possibility of symptomatic rhabdomyolysis as a potential side effect of emicizumab after moderate exertional activity.
Article PDF
Avoid common mistakes on your manuscript.
References
Alaygut D, Bayram MT, Kasap B, Soylu A, Türkmen M, Kavukcu S. Rhabdomyolysis with different etiologies in childhood. World J Clin Pediatr 2017;6;161–8.
Zimmerman JL, Shen MC. Rhabdomyolysis. Chest 2013;144; 1058–65.
Knochel JP. Mechanisms of rhabdomyolysis. Curr Opin Rheumatol 1993;5;725–31.
Genentech. Hemlibra: adverse reactions [Internet]. Available from: https://www.hemlibra.com/hcp/safety-side-effects/adverse-reactions.html (cited June 22, 2019).
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377;809–18.
Elsayed EF, Reilly RF. Rhabdomyolysis: a review, with emphasis on the pediatric population. Pedatr Nephrol 2010;25;7–18.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Wilson, J.A., Hayden, S., Asamoah, A. et al. Emicizumab Associated Rhabdomyolysis in Hemophilia A. Clin Hematol Int 2, 165–167 (2020). https://doi.org/10.2991/chi.k.200924.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.k.200924.001